Carcinoid Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Carcinoid clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 3

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Carcinoid TumorCarcinoid Tumor of PancreasCarcinoid Tumor of Liver+6 more
Crinetics Pharmaceuticals Inc.141 enrolled43 locationsNCT07087054
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+40 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Not Applicable

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Liver CancerBiliary Tract CancerColon Cancer+76 more
Cedars-Sinai Medical Center360 enrolled1 locationNCT04907643
Recruiting

Pharmaceutical Management in Targeted Radioligand Therapy

CancerThyroid CancerMetastatic Prostate Cancer+1 more
Hospices Civils de Lyon600 enrolled3 locationsNCT07389512
Recruiting
Phase 3

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Neuroendocrine TumorsGep NetCarcinoid Tumor+4 more
RayzeBio, Inc.288 enrolled54 locationsNCT05477576
Recruiting
Phase 2

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Metastatic Renal Cell CarcinomaNeuroendocrine TumorsCarcinoid Tumor+1 more
Fox Chase Cancer Center111 enrolled1 locationNCT05263050
Recruiting
Phase 2

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Peritoneal MesotheliomaAnaplastic Thyroid CarcinomasCarcinoid Tumor+3 more
Hospices Civils de Lyon154 enrolled15 locationsNCT06790706
Recruiting

ALG-LungCancerRegistry (SAFRO2202)

Carcinoma, Non-Small Cell LungLung NeoplasmsCarcinoma, Small Cell+1 more
Société Algérienne de Formation et de Recherche en Oncologie3,750 enrolled21 locationsNCT07161882
Recruiting
Not Applicable

Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.

Midgut Carcinoid TumorBiliary Stones
Hospital Universitari de Bellvitge100 enrolled6 locationsNCT04735198
Recruiting
Phase 2

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Neuroendocrine TumorsProgressionNeuroendocrine Tumor of Pancreas+4 more
AC Camargo Cancer Center100 enrolled2 locationsNCT06472388